I had the pleasure of speaking about preop cardiac risk assessment and periop med management at the CEC Primary Care Conference in Duck Key last week. cmemeeting.org
We’re seeing lower rates of postop CV complications in patients on GLP1 and SGLT2 drugs. Maybe time to change recommendations and have pts continue them preop???
Is this a scam?A “new” publication?New evidence reviewed-not a word changed! The 2026 Periop CV Mgmt Guideline reaffirms the 2024 guideline after reviewing evidence thru Mar 2026. Title updated to reflect reaffirmation but recommendations, text, figures, & tables remain unchanged
Preop GLP-1 RA use was associated with lower short-term postop mortality & reduced morbidity compared with metformin & DPP4’s, & no increased aspiration risk compared with any other drug class.